0001551986-20-000222.txt : 20200708 0001551986-20-000222.hdr.sgml : 20200708 20200708162951 ACCESSION NUMBER: 0001551986-20-000222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200706 FILED AS OF DATE: 20200708 DATE AS OF CHANGE: 20200708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sitar Edward J CENTRAL INDEX KEY: 0001603489 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37797 FILM NUMBER: 201018660 MAIL ADDRESS: STREET 1: 39 FLAMING ARROW ROAD CITY: MAHWAH STATE: NJ ZIP: 07430 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC. CENTRAL INDEX KEY: 0001551986 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273948465 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Monster Digital, Inc. DATE OF NAME CHANGE: 20150930 FORMER COMPANY: FORMER CONFORMED NAME: Tandon Digital, Inc. DATE OF NAME CHANGE: 20120611 4 1 wf-form4_159424017643845.xml FORM 4 X0306 4 2020-07-06 0 0001551986 9 METERS BIOPHARMA, INC. NMTR 0001603489 Sitar Edward J C/O 9 METERS BIOPHARMA, INC. 8480 HONEYCUTT RD, STE 120 RALEIGH NC 27615 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 0.6216 2020-07-06 4 A 0 550000 0 A 2030-07-06 Common stock 550000.0 550000 D Stock Option (Right to Buy) 0.6216 2020-07-06 4 A 0 225000 0 A 2030-07-06 Common stock 225000.0 775000 D 25% of these shares shall be deemed vested and exercisable on July 6, 2021 with the remainder vesting in equal monthly installments over the next 36 months, such that the option shall be fully vested on the fourth anniversary of the grant date, subject to the executive's continued service with the Company through each applicable vesting date. The option vest, if at all, upon satisfaction of certain performance criteria as determined by the Board in its discretion. Vesting will begin on the date the Board deems the performance criteria met (the "Performance Date"). Each performance tranche, consisting of 112,500 shares subject to the option, shall vest 25% on the one-year anniversary of the Performance Date with the remainder vesting monthly over 36 months following the Performance Date. /s/ Edward J. Sitar 2020-07-08